Roberts Glore & Co. Inc. IL increased its position in shares of Novartis AG (NYSE:NVS) by 1.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,065 shares of the company’s stock after buying an additional 200 shares during the period. Roberts Glore & Co. Inc. IL’s holdings in Novartis AG were worth $1,078,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Loomis Sayles & Co. L P raised its position in Novartis AG by 8.5% in the first quarter. Loomis Sayles & Co. L P now owns 5,242,948 shares of the company’s stock worth $379,800,000 after buying an additional 408,972 shares during the period. Woodley Farra Manion Portfolio Management Inc. bought a new position in Novartis AG during the second quarter worth $26,632,000. Cambiar Investors LLC raised its position in Novartis AG by 12.1% in the second quarter. Cambiar Investors LLC now owns 2,117,314 shares of the company’s stock worth $174,700,000 after buying an additional 229,198 shares during the period. Thomaspartners Inc. raised its position in Novartis AG by 14.7% in the first quarter. Thomaspartners Inc. now owns 1,484,339 shares of the company’s stock worth $107,526,000 after buying an additional 190,399 shares during the period. Finally, Bank of Montreal Can bought a new position in Novartis AG during the second quarter worth $15,682,000. Institutional investors and hedge funds own 9.78% of the company’s stock.
Shares of Novartis AG (NYSE:NVS) traded down 0.87% on Friday, hitting $76.09. The company had a trading volume of 4,034,245 shares. The firm has a 50 day moving average of $79.43 and a 200-day moving average of $78.94. The firm has a market capitalization of $181.19 billion, a P/E ratio of 27.17 and a beta of 0.57. Novartis AG has a 12-month low of $69.89 and a 12-month high of $95.11.
Novartis AG (NYSE:NVS) last posted its earnings results on Tuesday, July 19th. The company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.18 by $0.05. Novartis AG had a return on equity of 15.33% and a net margin of 13.84%. The firm earned $12.47 billion during the quarter, compared to analysts’ expectations of $12.33 billion. During the same period in the previous year, the firm earned $1.25 earnings per share. On average, equities analysts predict that Novartis AG will post $4.72 EPS for the current year.
NVS has been the subject of a number of recent analyst reports. Zacks Investment Research lowered Novartis AG from a “hold” rating to a “sell” rating in a research report on Wednesday, September 21st. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Novartis AG in a research report on Tuesday, July 19th. Chardan Capital decreased their price objective on Novartis AG from $95.00 to $92.00 and set a “buy” rating for the company in a research report on Monday. TheStreet upgraded Novartis AG from a “hold” rating to a “buy” rating in a research report on Friday, June 24th. Finally, Argus restated a “hold” rating on shares of Novartis AG in a research report on Thursday, August 25th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Novartis AG presently has an average rating of “Hold” and an average target price of $91.33.
Novartis AG Company Profile
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.